Skip to main content
Takeo Fujii, MD, Oncology, Bethesda, MD

Takeo Fujii MD , MPH

Oncology•Bethesda, MD

Breast Cancer

Assistant Clinical Investigator

Join to View Full Profile

  • 10 Center DrBethesda, MD 20892

  • Phone+1 240-858-3558

  • Fax+1 410-500-4266

Dr. Fujii is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Fujii's Full ProfileAlready have an account?

Summary

  • I am a board-certified medical oncologist and physician-scientist at National Cancer Institute, National Institutes of Health, Bethesda, MD. I take care of patients with breast cancer in NIH Clinical Center and conduct research. My research focuses on immune cells and inflammatory cells in tumor microenvironment, metastasis, and early phase clinical trials in breast cancer.

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellFellowship, Hematology and Medical Oncology, 2019 - 2022
  • University of Hawaii
    University of HawaiiResidency, Internal Medicine, 2016 - 2019
  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2016
  • University of Texas Health Science Center at Houston School of Public Health
    University of Texas Health Science Center at Houston School of Public HealthMPH, Biostatistics, 2013 - 2015
  • Other
    OtherClass of 2007

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2023 - 2026
  • MD State Medical License
    MD State Medical License 2023 - 2026
  • NY State Medical License
    NY State Medical License 2019 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Prior Systemic Treatment Increased the Incidence of Somatic Mutations in Metastatic Breast CancerJanuary 2018
  • Prior Systemic Treatment Increased the Incidence of Somatic Mutations in Metastatic Breast CancerJanuary 2018

Press Mentions

  • Treatment with Granulocyte-Colony Stimulating Factor (G-CSF) Is Not Associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast Cancer
    Treatment with Granulocyte-Colony Stimulating Factor (G-CSF) Is Not Associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast CancerJuly 25th, 2021
  • TrovaGene : Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to Be Presented at the AACR Annual Meeting 2016
    TrovaGene : Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to Be Presented at the AACR Annual Meeting 2016March 24th, 2016

Grant Support

  • Elucidating the role of thrombosis and inflammation in breast cancer metastasisDIVISION OF BASIC SCIENCES - NCIPresent
  • Elucidating the role of thrombosis and inflammation in breast cancer metastasisDIVISION OF BASIC SCIENCES - NCIPresent

Professional Memberships

Other Languages

  • Japanese

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Takeo Fujii, Dr. Takeo Fujii, MD, Dr. T Fujii